Venus Remedies Quarterly Results for Trading Insights
In Mar 2026, Venus Remedies (VENUSREM) reported revenue ₹264 Cr and net profit ₹48 Cr — revenue +30.7% YoY. Browse VENUSREM annual financials for revenue, profit, balance sheet and cash flow data.
VENUSREM Quarterly Results — Revenue, Profit & EPS Highlights
Venus Remedies latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore VENUSREM share price data to track price trends across different timeframes.
- Revenue of ₹264 Cr in Mar 2026 (+45.1% vs Jun 2026, +30.7% vs Mar 2025)
- Net Profit of ₹48 Cr in Mar 2026 (+108.7% vs Jun 2026, +128.6% vs Mar 2025)
- EBITDA of ₹68 Cr in Mar 2026 (+83.8% vs Jun 2026)
- Operating Margin of 24.0% in Mar 2026 (+5.0pp vs Jun 2026)
- Earnings Per Share of ₹35.53 in Mar 2026 (+106.8% vs Jun 2026)
Venus Remedies Quarterly Results — Revenue, EBITDA, Net Profit & EPS
VENUSREM quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 264 | 182 | 195 | 202 | 141 | 45.1% | 30.7% |
| Net Profit (₹ Cr) | 48 | 23 | 20 | 21 | 10 | - | - |
| EBITDA (₹ Cr) | 68 | 37 | 33 | 36 | 19 | - | - |
| EPS (₹) | 35.53 | 17.18 | 15.06 | 15.71 | 7.18 | - | - |
| Operating Margin (%) | 24.0% | 19.0% | 16.0% | 15.0% | 11.0% | - | - |
VENUSREM Share Price Trend — 1-Year Movement Across Quarterly Results
Venus Remedies 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Venus Remedies screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
VENUSREM vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Venus Remedies latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹463,071.60 Cr | 1875.1 | 15,018 | 2,710 | -5.6% | - | 18.0% | 165.9 |
|
Divis Laboratories
Mar 2026 |
₹225,157.18 Cr | 8588.0 | 2,986 | 751 | -5.0% | - | 25.2% | 303.4 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4971.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.9 |
|
Cipla
Mar 2026 |
₹117,137.57 Cr | 1431.1 | 6,612 | 543 | -9.3% | - | 8.2% | 208.3 |
|
Zydus Life Science
Mar 2026 |
₹113,855.38 Cr | 1115.6 | 7,569 | 1,341 | -4.3% | - | 17.7% | 88.2 |
All amounts in ₹ Crores